Liquid Biopsy with Emphasis on Cancer: Global Markets to 2023

May 2019 | 277 pages | ID: LFE5E4BE204EN
BCC Research

Abstracts

REPORT SCOPE:

The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2017, 2018 and 2023 (forecasted).

This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. The report discusses several significant, large-scale research initiatives that are contributing to liquid biopsy development. Key forces driving the market are enumerated.

The structures of several important industry subsectors are reviewed, as well as major industry acquisitions and strategic alliances from January 2017 through November 2018. Industry subsectors analyzed include advanced sequencing instruments, droplet digital PCR (polymerase chain reaction), target enrichment, single-cell DNA polymerase, non-invasive prenatal testing (NIPT), fetal-cell NIPT, CTC (circulating tumor cell) capture and detection and liquid biopsy.

The market for liquid biopsy diagnostics is analyzed in depth. The market is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics and other), analysis purpose (screening/ early detection, diagnosis, therapy guidance, monitoring) and geography (North America, Europe, Asia Pacific, Rest of the World).

Market data covers 2017, 2018 and 2023 (forecasted).

More than 175 companies in the liquid biopsy industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2017 through November 2018, including key alliance trends.

REPORT INCLUDES:

• 27 data tables and 70 additional tables
• An overview of the global markets for liquid biopsy technologies, applications, industry subsegments
• Analyses of global market trends with data from 2017 to 2018 and projections of compound annual growth rates (CAGRs) through 2023
• Regional dynamics of the liquid biopsy diagnostics market covering North America, Europe, APAC and rest of the world covering other emerging economies
• Discussion of major drivers, current trends and global outlook of liquid biopsy technologies, their growth potential and factors that influence the market
• Examination of various conventional biopsy methods and highlight how liquid biopsy enabling technologies address the issues and are gaining significant traction with key opinion leaders
• Comparative study of liquid biopsy with conventional biopsy technologies and coverage of their respective biomarkers
• Comprehensive company profiles of key market players within the industry, including Apocell Inc., Becton, Dickinson and Co., Clinical Genomics Technologies, Exact Sciences Corp. and Thermo Fisher Scientific Inc.

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY

CHAPTER 3 OVERVIEW

Introduction
Liquid Biopsy vs. Traditional Biopsy
Markets
Forces Driving Growth
Key Trends
Key Developments in Liquid Biopsy
Industry

CHAPTER 4 TECHNOLOGY BACKGROUND

Liquid Biopsy Biomarkers
Cancer Genomics
Invasive Prenatal Testing
Non-invasive Prenatal Testing (NIPT)
Circulating Tumor Cells (CTCs)
CTC Workflow
Liquid Biopsy vs. Conventional Biopsy
Cancer Testing

CHAPTER 5 LIQUID BIOPSY INITIATIVES

Immunomonitor Consortium (2018)
Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program (2018)
Liquid Biopsies and Imaging for Improved Cancer Care (2018)
Precancer Atlas (2018)
TopMed (2017)
Blood Profiling Atlas (2016)
Human Cell Atlas (2016)
Population Sequencing Projects (2016)
Cancer-ID (2015)
Precision Medicine Initiative (2015)
Early Cancer Detection Consortium (2014)
CTC Trap Consortium (2012)
EpiFemCare (2012)
Single-Cell Research (2012)
Cambridge Single-Cell Analysis Core Facility
Harvard Medical School Single-Cell Core
Mayo Medical Genome Facility
National Center for Single-Cell Biology
Single-Cell Analysis Core
UC San Francisco Single-Cell Analysis Center
Worldwide Innovative Networking (WIN) Consortium (2010)
Next-Generation Single-Cell Analysis Program
Single-Cell Proteomics and Lipidomics Project

CHAPTER 6 MARKET BREAKDOWN BY END USER

Introduction
Cancer Applications
Precision Medicine
Cancer Biomarker Status
Cancer Market Segments
NIPT Applications
Transplant Diagnostic Applications

CHAPTER 7 LIQUID BIOPSY INDUSTRY

Introduction
Advanced Sequencing Instruments Industry
NGS Instrument Industry
MiSeq
NextSeq
MiniSeq
ISeq
Ion Torrent
PromethIon
MinIon
GridION X5
Third-Generation Sequencing Industry
Droplet Digital PCR Industry
Target Enrichment and Amplification Industry
Single-cell DNA Polymerase Industry
Non-Invasive Prenatal Testing Industry
Fetal Cell NIPT Industry
CTC Capture and Detection Industry
Liquid Biopsy Assay Industry

CHAPTER 8 INDUSTRY ACQUISITIONS AND STRATEGIC ALLIANCES

Mergers and Acquisitions
Acquisitions
Strategic Alliances
Pipeline Analysis
Key Trends

CHAPTER 9 LIQUID BIOPSY MARKETS

Forces Driving Growth
Liquid Biopsy Market by Application
Liquid Biopsy Market by Biomarker Type
Liquid Biopsy Market by Analysis Platform
Liquid Biopsy Market by Analysis Purpose
Geographic Markets
Non-Invasive Prenatal Testing Market
Cancer Markets
Cancer Market by Disease Indication
Cancer Market by Analysis Purpose
Cancer Market by Biomarker Class
Cancer Market by Analysis Method
Breast Cancer Market
Colorectal Cancer Market
Hematological Cancer Market
Lung Cancer Market
Pan-Cancer Market
Transplant Markets
Regional Market Analysis

CHAPTER 10 PATENT REVIEW/ NEW DEVELOPMENTS

Circulating Tumor Cell Patents
Exosome Patents
Cell-free DNA Patents
Liquid Biopsy and Sequencing-Related Patent Issues

CHAPTER 11 COMPANY PROFILES

ACCURAGEN INC.
ADAPTIVE BIOTECHNOLOGIES INC.
ADVANCED CELL DIAGNOSTICS INC.
AGILENT TECHNOLOGIES, INC.
AKADEUM LIFE SCIENCES
ALCEDIAG
AMOY DIAGNOSTICS CO. LTD.
ANGLE PLC
APOCELL INC.
APOSTLE INC.
ARCEDI BIOTECH APS
ARUP LABORATORIES
ASURAGEN INC.
ATRECA INC.
AVIVA BIOSCIENCES
BAYLOR GENETICS
BECTON, DICKINSON AND CO.
BELLWETHER BIO INC.
BERRY GENOMICS CO. LTD.
BGI SHENZHEN
BIOCARTIS NV
BIOCEPT INC.
BIOCORE CO. LTD.
BIODESIX INC.
BIOFLUIDICA INC.
BIOGAZELLE
BIOMARX INC.
BIO-RAD LABORATORIES INC.
BIO-TECHNE LTD.
BIOVENDOR-LABORATORNI MEDICINA A.S.
BLUESTAR GENOMICS INC.
BOREAL GENOMICS
CANCER GENETICS INC.
CAREDX INC.
CEGAT GMBH
CELLMAX LIFE
CELL MICROSYSTEMS INC.
CELSEE DIAGNOSTICS
CHRONIX BIOMEDICAL
CIRCULOGENE THERANOSTICS
CIRCULOMICS INC.
CLINICAL GENOMICS TECHNOLOGIES
CODIAK BIOSCIENCES
COLOR GENOMICS
CS GENETICS LTD.
CYGNUS BIOSCIENCES CO. LTD.
CYNVENIO BIOSYSTEMS INC.
CYTOTRACK APS
DATAR CANCER GENETICS LTD.
DIACARTA INC.
DIAGNOLOGIX LLC
DIAGNOMICS
DIRECT GENOMICS CO. LTD.
DNA ELECTRONICS LTD.
DNALYTICS
DNANEXUS INC.
DOVETAIL GENOMICS LLC
ENVISION GENOMICS
EPIC SCIENCES INC.
EUROFINS SCIENTIFIC
EXACT SCIENCES CORP.
EXOSOME SCIENCES INC.
EXPEDEON AG
EZLIFE BIO INC.
FABRIC GENOMICS
FLUXION BIOSCIENCES INC.
FREENOME INC.
GENAPSYS INC.
GENEDX INC.
GENESEQ BIOSCIENCES PTY LTD.
GENETICS RESEARCH LLC
GENOMATIX GMBH
GENOMIC HEALTH INC.
GENOMONCOLOGY
GENOSPACE
GENEXOSOME TECHNOLOGIES INC.
GIGAGEN INC.
GOLDEN HELIX
GRAIL INC.
GUARDANT HEALTH INC.
HELITEC
HELIX OPCO LLC
HTG MOLECULAR DIAGNOSTICS INC.
ILLUMINA INC.
IMMUNOVIA AB
INEX INNOVATIONS EXCHANGE PTE. LTD.
INIVATA LTD.
INTERPACE DIAGNOSTICS LLC
INVITAE INC.
INVIVOSCRIBE INC.
JBS SCIENCE INC.
KONINKLIJKE PHILIPS N.V.
LABORATORY CORP. OF AMERICA INC.
LEXENT BIO INC.
LUCENCE DIAGNOSTICS PTE. LTD.
MAMMOTH BIOSCIENCES INC.
MDNA LIFE SCIENCES INC.
MDXHEALTH INC.
MEDGENOME LABS PVT. LTD.
MEDOMICS LLC
MENARINI SILICON BIOSYSTEMS SPA
MERCK KGAA
MOLECULAR HEALTH GMBH
MYRIAD GENETICS INC.
NAMOCELL INC.
NANOSTRING TECHNOLOGIES INC.
NANOVIEW BIOSCIENCES INC.
NATERA INC.
NAVERIS INC.
NEOGENOMICS LABORATORIES
NEW ENGLAND BIOLABS
NEW ONCOLOGY GMBH
NIPD GENETICS
N-OF-ONE INC.
NOVOGENE CO. LTD.
NUGEN TECHNOLOGIES INC.
NUPROBE INC.
NX PRENATAL INC.
ONCOCYTE CORP.
ONCODNA S.A.
OXFORD NANOPORE TECHNOLOGIES LTD.
PACIFIC BIOSCIENCES OF CALIFORNIA INC.
PANGAEA ONCOLOGY
PARADIGM DIAGNOSTICS INC.
PARSEQ LAB CO. LTD.
PATHWAY GENOMICS CORP.
PERSONAL GENOME DIAGNOSTICS INC.
PIERIANDX
PORTABLE GENOMICS LLC
PRECIPIO INC.
PREDICINE INC.
PREMAITHA HEALTH PLC
PRENETICS
PROVISTA DIAGNOSTICS INC.
QIAGEN NV
QUANTAPORE INC.
QUANTUM BIOSYSTEMS INC.
QUANTUMDX
QUEST DIAGNOSTICS INC.
RARECELLS SAS
RARECYTE INC.
REAL TIME GENOMICS INC.
RESOLUTION BIOSCIENCE INC.
ROCHE HOLDING AG
SCREENCELL
SEEKIN
SENGENICS LTD.
SEQUENCING.COM
SEVEN BRIDGES GENOMICS INC.
SINGLERA GENOMICS INC.
SOPHIA GENETICS
SPERA MEDICAL
SPHERE FLUIDICS LTD.
STILLA TECHNOLOGIES
STRAND LIFE SCIENCES PVT. LTD.
STRATOS GENOMICS INC.
SYAPSE
SYSMEX INOSTICS GMBH
TAI DIAGNOSTICS INC.
TAKARA BIO INC.
THERMO FISHER SCIENTIFIC INC.
THORNE DIAGNOSTICS INC.
TRANSPLANT GENOMICS
TROVAGENE INC.
TWINSTRAND BIOSCIENCES
TWO PORE GUYS INC.
TYMORA ANALYTICAL OPERATIONS LLC
UBIQUITY GENOMICS INC.
VORTEX BIOSCIENCES
VELA DIAGNOSTICS
VOLITIONRX
VORTEX BIOSCIENCES
XING TECHNOLOGIES LLC
YIKON GENOMICS CO. LTD.

List Of Tables

LIST OF TABLES

Summary Table: Global Liquid Biopsy Market, by Disease Class, Through 2023
Table 1: Liquid Biopsy Sample Types
Table 2: Liquid Biopsy: Report Scope
Table 3: Global Liquid Biopsy Market, by Analysis Type, Through 2023
Table 4: Forces Driving Growth
Table 5: Key Trends in the Liquid Biopsy Market
Table 6: Liquid Biopsy Industry Subsectors
Table 7: Liquid Biopsy: Biomarker Classes
Table 8: Clinical Implications of CTCs
Table 9: Key Applications of Circulating Tumor DNA (ctDNA)
Table 10: Applications of ctDNA, CTCs and Exosomes
Table 11: Single-Cell Analysis to Identify Cancer Driver Mutations
Table 12: Genomics-Based Oncology Workflow
Table 13: Prenatal Invasive Testing Technologies
Table 14: Invasive and Non-Invasive Prenatal Technologies
Table 15: Unique Challenges: CTC Capture and Analysis
Table 16: CTC Workflow
Table 17: Cell Differentiators
Table 18: Cell Isolation Technologies
Table 19: CTC-Isolating Markers
Table 20: CTC Sample Preparation Technologies
Table 21: Single-Cell Analysis Technologies
Table 22: Limitations of Conventional Biopsy
Table 23: Liquid vs. Traditional Biopsy
Table 24: Estimated Annual Solid Biopsy Procedures in the U.S.: Selected Cancers
Table 25: Main Risks: Needle-Based Tissue Biopsies
Table 26: Factors in Tissue Biopsy
Table 27: Liquid Biopsy Research and Development Programs, 2010-2018
Table 28: Single-Cell Core Research Facilities
Table 29: Source of Foreign Biomarkers for Liquid Biopsy Applications
Table 30: Personalized Medicine for Common Cancer Genetic Mutations
Table 31: Clinical Status of Cancer Biomarkers in Liquid Biopsy
Table 32: Cancer Liquid Biopsy Market Segments
Table 33: Reproductive Health Screening Applications
Table 34: Ethical Issues Associated with NIPT
Table 35: Transplant Diagnostic Applications
Table 36: Key Segments and Trends: Liquid Biopsy Industry
Table 37: Advanced Sequencing Industry Company Positioning
Table 38: End-to-End Sequencing Approaches
Table 39: Next-Generation Sequencing Instrument Companies
Table 40: NGS Instruments
Table 41: Benchtop and Handheld Sequencer Platforms
Table 42: 3GS Industry, by Tier Status
Table 43: Advantages of Droplet Digital PCR for Single-Cell Analysis
Table 44: Digital PCR Liquid Biopsy Industry
Table 45: Target Enrichment Industry
Table 46: Single-Cell DNA Polymerase Industry
Table 47: Major Companies Associated with the NIPT Industry
Table 48: Estimated Number of NIPT Assays, by Company, 2018
Table 49: Germany NGS-Based Non-Invasive Prenatal Diagnostic Companies, 2017
Table 50: NIPT Test Licensing, by Country
Table 51: Fetal Cell NIPT Industry
Table 52: CTC Separations Industry
Table 53: Liquid Biopsy Assay Industry: Company Focus
Table 54: NGS-Based Liquid Biopsy Market Differentiation
Table 55: Liquid Biopsy Industry: Mergers and Acquisitions of Key Players, 2016-2018
Table 56: Liquid Biopsy: Industry Acquisitions, January 2017 Through November 2018
Table 57: Liquid Biopsy: Strategic Alliances, January 2017 Through November 2018
Table 58: Liquid Biopsy: Pipeline Analysis, January 2017 Through December 2018
Table 59: Liquid Biopsy: Forces Driving Growth and Implications Through 2023
Table 60: Global Liquid Biopsy Market, by Application, Through 2023
Table 61: Global Liquid Biopsy Market, by Biomarker Type, Through 2023
Table 62: FDA-Approved or CE-Marked Tests with Epigenetic Component
Table 63: Global Liquid Biopsy Market, by Analysis Platform, Through 2023
Table 64: Global Liquid Biopsy Market, by Analysis Purpose, Through 2023
Table 65: Global Liquid Biopsy Market, by Region, Through 2023
Table 66: Global Market for Liquid Biopsy in NIPT Applications, by Analysis Purpose, Through 2023
Table 67: Global Market for Liquid Biopsy in NIPT Applications, by Risk Type, Through 2023
Table 68: Global Market for Liquid Biopsy in NIPT Applications, by Biomarker Class, Through 2023
Table 69: Global Market for Liquid Biopsy in NIPT Applications, by Analysis Method, Through 2023
Table 70: Limitations of Solid/Tissue Biopsy in Cancer Applications
Table 71: Low-Frequency Mutation Detection
Table 72: Global Market for Liquid Biopsy in Cancer Applications, by Disease Indication, Through 2023
Table 73: Five-Year Survival Rate for Ovarian Cancer
Table 74: NIH Liquid Biopsy Early Detection Initiative
Table 75: Molecular Thyroid Nodule Classifier Tests
Table 76: Global Market for Liquid Biopsy in Cancer Applications, by Analysis Purpose, Through 2023
Table 77: MRI and Liquid Biopsy Methods
Table 78: Early Detection Tissue of Origin Approaches
Table 79: Global Market for Liquid Biopsy in Cancer Applications, by Biomarker Class, Through 2023
Table 80: Global Market for Liquid Biopsy in Cancer Applications, by Analysis Method, Through 2023
Table 81: Global Market for Liquid Biopsy in Breast Cancer Applications, by Analysis Method, Through 2023
Table 82: Global Market for Liquid Biopsy in Colorectal Cancer Applications, by Analysis Method, Through 2023
Table 83: Global Market for Liquid Biopsy in Hematological Cancer Applications, by Analysis Method, Through 2023
Table 84: Global Market for Liquid Biopsy in Lung Cancer Applications, by Analysis Method, Through 2023
Table 85: Global Market for Liquid Biopsy in Pan-Cancer Applications, by Analysis Method, Through 2023
Table 86: Global Market for Liquid Biopsy in Transplant Applications, by Analysis Purpose, Through 2023
Table 87: Global Market for Liquid Biopsy in Transplant Applications, by Organ Type, Through 2023
Table 88: Transplant Procedures Performed in the United States, 2016 Through September 2018
Table 89: Global Market for Liquid Biopsy in Transplant Applications, by Analysis Method, Through 2023
Table 90: Global Market for Liquid Biopsy in Transplant Applications, by Biomarker Class, Through 2023
Table 91: Global Market for Liquid Biopsy in Cancer Applications, by Region, Through 2023
Table 92: Global Market for Liquid Biopsy in NIPT Applications, by Region, Through 2023
Table 93: Global Market for Liquid Biopsy in Transplant Application, by Region, Through 2023
Table 94: Patent Activity for Circulating Tumor Cells (CTCs), by Country/Region, 2008-2018
Table 95: Patent Activity for Exosomes, by Country/Region, 2008-2018
Table 96: Patent Activity for Cell-Free DNA (cfDNA) by Country/Region, 2008-2018
Table 97: Liquid Biopsy and Sequencing-Related Patent Disputes

List Of Figures

LIST OF FIGURES

Summary Figure: Global Liquid Biopsy Market, by Disease Class, 2017-2023
Figure 1: Timeline of Liquid Biopsy Development
Figure 2: Molecular Applications of Biomarkers as Liquid Biopsy for Personalized Medicine
Figure 3: How Cancer Genomics Drive Liquid Biopsy
Figure 4: Clinical Applications of Liquid Biopsy for Precision Medicine
Figure 5: Shedding of Circulating Tumor Cells